Unidad de ETV HGUGM
@etvgregorio.bsky.social
Unidad de Enfermedad Tromboembólica Venosa del Hospital Gregorio Marañón/VTE Unit, Hospital Gregorio Marañón.
Madrid, Spain.
#MedSky #VTESky #HemeSky #thrombosis
Madrid, Spain.
#MedSky #VTESky #HemeSky #thrombosis
Whenever you see a young male with EN and DVT, always remember to ask about oral&genital ulcers!
#VTE #thrombosis #Behçet #IMSky
#VTE #thrombosis #Behçet #IMSky
June 9, 2025 at 9:31 PM
Whenever you see a young male with EN and DVT, always remember to ask about oral&genital ulcers!
#VTE #thrombosis #Behçet #IMSky
#VTE #thrombosis #Behçet #IMSky
This vasculitis may show multiple symptoms.
The International Criteria may be helpful in the diagnosis:
The International Criteria may be helpful in the diagnosis:
June 9, 2025 at 9:31 PM
This vasculitis may show multiple symptoms.
The International Criteria may be helpful in the diagnosis:
The International Criteria may be helpful in the diagnosis:
This goes in line with current guidelines, but we now have further evidence to support these claims.
Find the entire paper here, free of charge:
www.sciencedirect.com/science/arti...
Find the entire paper here, free of charge:
www.sciencedirect.com/science/arti...
Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis
Antithrombotic therapy can prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is, however, associated with an increased risk…
www.sciencedirect.com
April 10, 2025 at 5:27 AM
This goes in line with current guidelines, but we now have further evidence to support these claims.
Find the entire paper here, free of charge:
www.sciencedirect.com/science/arti...
Find the entire paper here, free of charge:
www.sciencedirect.com/science/arti...
A recent metaanalysis including 22 articles states that:
⌚️ Transient risk factor: 3-6 months of treatment superior to extended therapy.
🛌 Unprovoked VTE or chronic provoking factor: extended therapy is superior to limited.
⌚️ Transient risk factor: 3-6 months of treatment superior to extended therapy.
🛌 Unprovoked VTE or chronic provoking factor: extended therapy is superior to limited.
April 10, 2025 at 5:27 AM
A recent metaanalysis including 22 articles states that:
⌚️ Transient risk factor: 3-6 months of treatment superior to extended therapy.
🛌 Unprovoked VTE or chronic provoking factor: extended therapy is superior to limited.
⌚️ Transient risk factor: 3-6 months of treatment superior to extended therapy.
🛌 Unprovoked VTE or chronic provoking factor: extended therapy is superior to limited.
Results:
🫁 Non inferiority for recurrence or mortality.
🩸Less bleeding events with apixaban 2.5 mg.
This is a question many of us have asked ourselves when facing cancer patients in our clinical practice, and now we finally have an answer.
🫁 Non inferiority for recurrence or mortality.
🩸Less bleeding events with apixaban 2.5 mg.
This is a question many of us have asked ourselves when facing cancer patients in our clinical practice, and now we finally have an answer.
April 1, 2025 at 9:15 PM
Results:
🫁 Non inferiority for recurrence or mortality.
🩸Less bleeding events with apixaban 2.5 mg.
This is a question many of us have asked ourselves when facing cancer patients in our clinical practice, and now we finally have an answer.
🫁 Non inferiority for recurrence or mortality.
🩸Less bleeding events with apixaban 2.5 mg.
This is a question many of us have asked ourselves when facing cancer patients in our clinical practice, and now we finally have an answer.
Recently published in @nejm.org, API-CAT:
👯 1766 cancer patients.
🎂 69 years old.
👨🦰43.4% men.
🦵 Included, in average, 8 months after VTE.
🗓️ Median follow-up 11.8 months.
💊 Apixaban 2.5 mg vs 5 mg twice daily.
👯 1766 cancer patients.
🎂 69 years old.
👨🦰43.4% men.
🦵 Included, in average, 8 months after VTE.
🗓️ Median follow-up 11.8 months.
💊 Apixaban 2.5 mg vs 5 mg twice daily.
April 1, 2025 at 9:15 PM
Recently published in @nejm.org, API-CAT:
👯 1766 cancer patients.
🎂 69 years old.
👨🦰43.4% men.
🦵 Included, in average, 8 months after VTE.
🗓️ Median follow-up 11.8 months.
💊 Apixaban 2.5 mg vs 5 mg twice daily.
👯 1766 cancer patients.
🎂 69 years old.
👨🦰43.4% men.
🦵 Included, in average, 8 months after VTE.
🗓️ Median follow-up 11.8 months.
💊 Apixaban 2.5 mg vs 5 mg twice daily.
You might remember the EVE trial (2023):
💊 apixaban 2.5 mg vs 5 mg twice daily in cancer patients with VTE after 6-12 months of treatment.
🩸Primary outcome: bleeding.
🗓️ Follow-up: 12 months.
👯360 patients included in analysis.
Shockingly, apixaban 2.5 mg did not reduce bleeding compared to 5 mg.
💊 apixaban 2.5 mg vs 5 mg twice daily in cancer patients with VTE after 6-12 months of treatment.
🩸Primary outcome: bleeding.
🗓️ Follow-up: 12 months.
👯360 patients included in analysis.
Shockingly, apixaban 2.5 mg did not reduce bleeding compared to 5 mg.
April 1, 2025 at 9:15 PM
You might remember the EVE trial (2023):
💊 apixaban 2.5 mg vs 5 mg twice daily in cancer patients with VTE after 6-12 months of treatment.
🩸Primary outcome: bleeding.
🗓️ Follow-up: 12 months.
👯360 patients included in analysis.
Shockingly, apixaban 2.5 mg did not reduce bleeding compared to 5 mg.
💊 apixaban 2.5 mg vs 5 mg twice daily in cancer patients with VTE after 6-12 months of treatment.
🩸Primary outcome: bleeding.
🗓️ Follow-up: 12 months.
👯360 patients included in analysis.
Shockingly, apixaban 2.5 mg did not reduce bleeding compared to 5 mg.
We hope this evidence helps in your daily practice!
@luciaordieres.bsky.social
#anticoagulation #thrombosis #hematology #HemeSky #ThromboSky #VTESky #Medicine
@luciaordieres.bsky.social
#anticoagulation #thrombosis #hematology #HemeSky #ThromboSky #VTESky #Medicine
March 8, 2025 at 9:49 PM
We hope this evidence helps in your daily practice!
@luciaordieres.bsky.social
#anticoagulation #thrombosis #hematology #HemeSky #ThromboSky #VTESky #Medicine
@luciaordieres.bsky.social
#anticoagulation #thrombosis #hematology #HemeSky #ThromboSky #VTESky #Medicine
❓TUS may pose a management challenge due to the lack of solid evidence.
💊We compared 161 patients treated with DOACs vs VKAs.
⛑️Overall, no differences in major bleeding or recurrences.
🧪DOACs: Pharmacokinetic advantages.
🍺Need to individualize in some populations (liver disease...).
💊We compared 161 patients treated with DOACs vs VKAs.
⛑️Overall, no differences in major bleeding or recurrences.
🧪DOACs: Pharmacokinetic advantages.
🍺Need to individualize in some populations (liver disease...).
March 8, 2025 at 9:49 PM
❓TUS may pose a management challenge due to the lack of solid evidence.
💊We compared 161 patients treated with DOACs vs VKAs.
⛑️Overall, no differences in major bleeding or recurrences.
🧪DOACs: Pharmacokinetic advantages.
🍺Need to individualize in some populations (liver disease...).
💊We compared 161 patients treated with DOACs vs VKAs.
⛑️Overall, no differences in major bleeding or recurrences.
🧪DOACs: Pharmacokinetic advantages.
🍺Need to individualize in some populations (liver disease...).